scholarly journals Review of Hyperuricemia as New Marker for Metabolic Syndrome

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Laura Billiet ◽  
Sarah Doaty ◽  
James D. Katz ◽  
Manuel T. Velasquez
Keyword(s):  
Metabolic Syndrome ◽  
Uric Acid ◽  
Lupus Erythematosus ◽  
Large Body ◽  
Epidemiologic Studies ◽  
Etiologic Factor ◽  
Systemic Diseases ◽  
Systemic Lupus ◽  
The Metabolic Syndrome

Hyperuricemia has long been established as the major etiologic factor in gout. In recent years, a large body of evidence has accumulated that suggests that hyperuricemia may play a role in the development and pathogenesis of a number of metabolic, hemodynamic, and systemic pathologic diseases, including metabolic syndrome, hypertension, stroke, and atherosclerosis. A number of epidemiologic studies have linked hyperuricemia with each of these disorders. In some studies, therapies that lower uric acid may prevent or improve certain components of the metabolic syndrome. There is an association between uric acid and the development of systemic lupus erythematosus; the connection between other rheumatic diseases such as rheumatoid arthritis and osteoarthritis is less clear. The mechanism for the role of uric acid in disorders other than gout is not well established but recent investigations point towards systemic inflammation induced by urate, as the major pathophysiological event common to systemic diseases, including atherosclerosis.

Metabolic Syndrome Is Associated with Increased Arterial Stiffness and Biomarkers of Subclinical Atherosclerosis in Patients with Systemic Lupus Erythematosus

2009 ◽  
Vol 36 (10) ◽  
pp. 2204-2211 ◽  
Author(s):  
JOSÉ MARIO SABIO ◽  
JOSÉ VARGAS-HITOS ◽  
MÓNICA ZAMORA-PASADAS ◽  
JUAN DIEGO MEDIAVILLA ◽  
NURIA NAVARRETE ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Metabolic Syndrome ◽  
Uric Acid ◽  
Lupus Erythematosus ◽  
Subclinical Atherosclerosis ◽  
Glycosylated Hemoglobin ◽  
Atherosclerotic Cardiovascular Disease ◽  
Homa Index ◽  
Systemic Lupus ◽  
D Dimer

Objective.Aortic pulse wave velocity (PWV) is an independent predictor of risk for atherosclerotic cardiovascular disease. Metabolic syndrome (MetS) is more prevalent in patients with systemic lupus erythematosus (SLE) compared with matched healthy subjects. Aortic PWV is increased in MetS. The purpose of this cross-sectional study was to determine the association between MetS and aortic PWV and other surrogate biomarkers of subclinical atherosclerosis in SLE.Methods.One hundred twenty-eight patients with SLE were studied. We established the presence of MetS according to the National Cholesterol Education Program Adult Treatment Panel III definition and we measured PWV, glucose, insulin, glycosylated hemoglobin (HbA1c), insulin sensitivity (HOMA index), lipid levels, uric acid, homocysteine, fibrinogen, D-dimer, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), interleukin 6 (IL-6), IL-8, IL-10, C3, C4, autoantibodies, SLE Disease Activity Index (SLEDAI), and Systemic Lupus International Collaborating Clinics/ACR Damage Index. Duration of SLE and treatment was also recorded. Multivariate logistic regression analysis was used to identify independent determinants of increased PWV.Results.SLE patients with MetS had higher aortic PWV (9.8 ± 2.4 vs 8.5 ± 1.7 m/s; p = 0.002) and increased biomarkers of subclinical atherosclerosis such as CRP, IL-6, C3, uric acid, homocysteine, fibrinogen and D-dimer, compared to those without MetS. HOMA index and insulin and HbA1c levels were also higher in this group. No differences were found in variables related to lupus activity (ESR, C4, SLEDAI, IL-8, IL-10, and treatment for SLE). In the multivariate model, increased PWV was associated with age, male sex, MetS, duration of SLE, and CRP.Conclusion.MetS may contribute to the development of accelerated atherosclerosis in SLE.

Adipokines and Systemic Lupus Erythematosus: Relationship with Metabolic Syndrome and Cardiovascular Disease Risk Factors

2009 ◽  
Vol 36 (2) ◽  
pp. 295-297 ◽  
Author(s):  
MARTA VADACCA ◽  
DOMENICO MARGIOTTA ◽  
AMELIA RIGON ◽  
FABIO CACCIAPAGLIA ◽  
GIUSY COPPOLINO ◽  
...  
Keyword(s):  
Risk Factors ◽  
Systemic Lupus Erythematosus ◽  
Cardiovascular Disease ◽  
Metabolic Syndrome ◽  
Lupus Erythematosus ◽  
Disease Risk ◽  
Activity Index ◽  
Cardiovascular Disease Risk ◽  
Systemic Lupus ◽  
The Metabolic Syndrome

Objective.To study concentrations of adipokines in patients with systemic lupus erythematosus (SLE) and the relationship among adipokines, the metabolic syndrome (MeS), and cardiovascular disease (CVD) risk factors.Methods.We enrolled 50 SLE patients and 26 controls, all women. Leptin, resistin, visfatin, and adiponectin were measured by commercial ELISA kits.Results.MeS prevalence was increased among subjects with SLE. Leptin levels were higher in patients with SLE than controls. Among SLE patients, independent determinants of leptin were insulin levels (p < 0.0001), triglycerides (p = 0.03), body mass index (p = 0.02), corticosteroid dosage (p = 0.02), and SLE Disease Activity Index (p = 0.005). Other adipokines did not differ between SLE patients and controls.Conclusion.Leptin was increased in SLE patients and could play a role in SLE-related cardiovascular diseases.

Sign in / Sign up

Export Citation Format

Share Document